NASDAQ:HEPA Hepion Pharmaceuticals Q2 2026 Earnings Report $0.07 0.00 (-5.60%) As of 01:07 PM Eastern ProfileEarnings History Hepion Pharmaceuticals EPS ResultsActual EPS-$0.08Consensus EPS -$200.00Beat/MissBeat by +$199.92One Year Ago EPSN/AHepion Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHepion Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time7:00AM ETUpcoming EarningsHepion Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Hepion Pharmaceuticals Earnings HeadlinesHepion Pharmaceuticals Announces New Private Placement FinancingAugust 4, 2026 | tipranks.comHepion Shareholders Expand Equity Plan at 2026 MeetingJune 17, 2026 | tipranks.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.August 21 at 1:00 AM | Profits Run (Ad)Hepion Pharmaceuticals Announces Private Placement Financing AgreementApril 22, 2026 | tipranks.comHepion Finalizes CEO Separation Agreement Amid Leadership TransitionApril 14, 2026 | tipranks.comHepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular CarcinomaMarch 3, 2026 | globenewswire.comSee More Hepion Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hepion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hepion Pharmaceuticals and other key companies, straight to your email. Email Address About Hepion PharmaceuticalsHepion Pharmaceuticals (NASDAQ:HEPA) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases. The company harnesses epigenetic and autophagy‐modulating approaches to address high unmet medical needs in conditions such as nonalcoholic steatohepatitis (NASH), fibrosis and hepatocellular carcinoma. Hepion’s research platform is designed to identify and advance small molecules that can halt or reverse liver damage by targeting key pathways involved in inflammation, cellular stress and tissue remodeling. The company’s lead therapeutic candidate, CRV431, is a cyclophilin inhibitor being evaluated in Phase 2 clinical trials for the treatment of NASH with bridging fibrosis. CRV431 has demonstrated the potential to reduce inflammation, fibrosis and lipid accumulation in preclinical models. In addition to CRV431, Hepion’s pipeline includes early‐stage compounds aimed at inhibiting VPS34, an enzyme involved in autophagy, which may offer complementary mechanisms to improve liver function and slow disease progression. Hepion collaborates with academic institutions and contract research organizations to advance its programs from preclinical development into human studies. Hepion Pharmaceuticals is headquartered in the United States and conducts multi‐center trials across North America and Europe. The company is led by a management team with extensive experience in pharmaceutical development, regulatory strategy and commercialization. Hepion seeks to leverage its scientific expertise and strategic partnerships to deliver safe and effective therapies for patients suffering from chronic liver disorders.View Hepion Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Microsoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?Advance Auto Parts Plunged, But Its Turnaround Is Still WorkingWalmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-EndMeta Platform's Legal Issues Could Become Much More Than A Q2 Earnings Headache Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
